Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2014-10-30 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2014年第三季度报告全文
Interim / Quarterly Report Classification · 98% confidence The document is titled as the "2014 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow data, and notes on financial performance for the third quarter of 2014. The document includes comprehensive financial data and analysis for a period shorter than a full fiscal year, which matches the definition of an Interim / Quarterly Report (IR). The length of the document (15,000 characters) and the presence of actual financial statements confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. 9M 2014
2014-10-30 Chinese
2014年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2014 Third Quarter Report" of 华兰生物工程股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, cash flow, and shareholder information for the third quarter of 2014. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is over 7,000 characters and contains substantive financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2014
2014-10-30 Chinese
关于全资子公司取得产品生产批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding a subsidiary obtaining a production permit for a product, issued by a regulatory authority (国家食品药品监督管理总局). It is a formal company announcement about a regulatory approval, not a financial report, management change, or shareholder meeting material. The length is only 437 characters, indicating it is a brief announcement. It does not contain financial data, voting results, or executive changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-10-28 Chinese
关于滑县单采血浆站取得单采血浆许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the company receiving a license for plasma collection from a local health authority. It is a regulatory announcement about a permit/license, not a financial report, management change, or shareholder meeting material. The document length is very short (377 characters), and it does not contain financial data or detailed report content. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2014-09-23 Chinese
关于参股子公司单克隆抗体药物研发进展的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from 华兰生物工程股份有限公司 regarding the progress of clinical research applications for monoclonal antibody drugs by its subsidiary. It includes risk warnings about the regulatory review process by the National Medical Products Administration and states that the clinical research applications have been accepted for review. The document does not contain financial statements, audit information, or detailed financial data. It is an update on a specific business development related to drug research progress, which is a regulatory announcement about ongoing clinical trial application status. The document length is short (961 characters) and it is clearly an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-09-22 Chinese
关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of a senior management member (vice general manager) of the company. It includes no financial data, no report references, and is focused solely on management changes. The document length is only 404 characters, indicating it is a brief announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2014-09-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.